Ratliff T L, Gillen D, Catalona W J
J Urol. 1987 Jan;137(1):155-8. doi: 10.1016/s0022-5347(17)43909-7.
Surgical adjuvant intravesical bacille Calmette-Guerin (BCG) therapy is an effective method of treating superficial transitional cell carcinoma of the bladder. The role of the immune response in the antitumor activity of intravesical BCG is not known. We investigated the requirement of a thymus-dependent immune response for the inhibition of the growth of the intravesically implanted mouse bladder tumor, MBT-2. Intravesical BCG had no antitumor activity when administered to athymic nude mice bearing MBT-2 tumors. In two experiments tumor outgrowth in control and BCG-treated mice was identical. Adoptive transfer of BCG sensitized splenocytes (one spleen equivalent per mouse injected intravenously immediately prior to the first BCG treatment) syngeneic to the MBT-2 tumor transferred delayed hypersensitivity reactivity to BCG antigens and restored the antitumor activity of intravesical BCG. In two separate experiments mice receiving splenocytes plus BCG had 0 and 20% tumor outgrowth compared with 100% in control mice (p less than .02 and p less than .05, respectively). These results demonstrate that the antitumor activity of intravesical BCG therapy requires a thymus-dependent immune response.
手术辅助膀胱内卡介苗（BCG）治疗是治疗浅表性膀胱移行细胞癌的有效方法。免疫反应在膀胱内卡介苗抗肿瘤活性中的作用尚不清楚。我们研究了胸腺依赖性免疫反应对抑制膀胱内植入的小鼠膀胱肿瘤MBT-2生长的必要性。当给携带MBT-2肿瘤的无胸腺裸鼠膀胱内注射卡介苗时，其没有抗肿瘤活性。在两项实验中，对照小鼠和接受卡介苗治疗的小鼠的肿瘤生长情况相同。将与MBT-2肿瘤同基因的卡介苗致敏脾细胞（在首次卡介苗治疗前立即静脉注射，每只小鼠注射一个脾当量）进行过继转移，可将对卡介苗抗原的迟发型超敏反应性转移给受体，并恢复膀胱内卡介苗的抗肿瘤活性。在两项独立实验中，接受脾细胞加卡介苗治疗的小鼠肿瘤生长率分别为0和20%，而对照小鼠为100%（p分别小于0.02和p小于0.05）。这些结果表明，膀胱内卡介苗治疗的抗肿瘤活性需要胸腺依赖性免疫反应。
